Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Arcus Biosciences Inc. (RCUS) Insider Trading Activity
Healthcare • Biotechnology • 577 employees
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
Total Value
-$1,488,047.07
Total Shares
349,359
Average Trade Value
-$78,318.27
Most Active Insider
Rosen Terry J
Total Activity: $810,608
Largest Single Transaction
$609,143
by Rosen Terry J on Dec 15, 2024
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Director
|
Feb 27, 2025 | 20,000 | $201,200 | 28,400 (+70.4%) | Purchase | |
|
Chief Executive Officer
Director, Officer
|
Feb 27, 2025 | 19,800 | $201,465 | 2,554,160 (+0.8%) | Purchase | |
|
Chief Medical Officer
Officer
|
Feb 10, 2025 | 75,193 | $10,000 | 75,193 (+100.0%) | Grant | |
|
President
Officer
|
Jan 23, 2025 | 50,000 | $10,000 | 367,220 (+13.6%) | Grant | |
|
Chief Executive Officer
Director, Officer
|
Jan 23, 2025 | 165,000 | $0 | 2,534,360 (+6.5%) | Grant | |
|
General Counsel
Officer
|
Jan 23, 2025 | 37,000 | $10,000 | 137,623 (+26.9%) | Grant | |
|
Chief Accounting Officer
Officer
|
Jan 23, 2025 | 17,100 | $10,000 | 30,194 (+56.6%) | Grant | |
|
Chief Financial Officer
Officer
|
Jan 23, 2025 | 37,000 | $10,000 | 97,138 (+38.1%) | Grant | |
|
Chief Operating Officer
Officer
|
Jan 23, 2025 | 50,000 | $10,000 | 213,369 (+23.4%) | Grant | |
|
Chief Financial Officer
Officer
|
Dec 31, 2024 | 3,594 | $53,910 | 60,138 (-6.0%) | Sale | |
|
Chief Accounting Officer
Officer
|
Dec 19, 2024 | 3,007 | $45,616 | 13,094 (-23.0%) | Sale to Issuer | |
|
Chief Medical Officer
Officer
|
Dec 15, 2024 | 7,856 | $126,324 | 87,518 (-9.0%) | Payment of Exercise Price | |
|
Chief Accounting Officer
Officer
|
Dec 15, 2024 | 2,969 | $47,742 | 16,101 (-18.4%) | Payment of Exercise Price | |
|
Chief Executive Officer
Director, Officer
|
Dec 15, 2024 | 37,882 | $609,143 | 2,369,360 (-1.6%) | Payment of Exercise Price | |
|
President
Officer
|
Dec 15, 2024 | 17,286 | $277,959 | 317,220 (-5.4%) | Payment of Exercise Price | |
|
Chief Financial Officer
Officer
|
Dec 15, 2024 | 10,099 | $162,392 | 63,732 (-15.8%) | Payment of Exercise Price | |
|
Chief Operating Officer
Officer
|
Dec 15, 2024 | 27,501 | $442,216 | 163,369 (-16.8%) | Payment of Exercise Price | |
|
General Counsel
Officer
|
Dec 15, 2024 | 11,339 | $182,331 | 100,623 (-11.3%) | Payment of Exercise Price | |
|
Chief Accounting Officer
Officer
|
Dec 2, 2024 | 201 | $3,079 | 19,070 (-1.1%) | Sale |